MRK - Merck & Co., Inc.
| Previous Close | 63.220 |
| Open | 64.090 |
| Bid | 63.490 x 1900 |
| Ask | 63.500 x 1000 |
| Day's Range | 63.410 - 64.110 |
| 52 Week Range | 58.290 - 66.800 |
| Volume | 3,312,037 |
| Avg. Volume | 7,709,275 |
| Market Cap | 173.23B |
| Beta | 0.94 |
| PE Ratio (TTM) | 34.39 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.88 (2.85%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- TheStreet.com•3 hours ago
Merck Stock Edges Higher as Citi Forecasts Strong Sales
Citi analysts say Merck's Keytruda immunotherapy cancer drug will carry the company.
- Benzinga•3 hours ago
Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever
Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK ). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from ...
- CNBC•3 hours ago
Merck shares jump after Citi upgrade on stronger cancer drug sales
Keytruda is an immunotherapy drug used in cancer treatments. Citi increased its peak Keytruda sales forecast on the drug to $16 billion from $9 billion.
- Market Realist•21 hours ago
Behind Merck’s Performance in 3Q17
MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.
- MarketWatch•2 days ago
Lost beneath headlines of five-figure drug costs — pharmaceutical price growth is weakening
After months of headlines about astronomical drug prices, a funny thing’s happening — drug costs are plummeting.
- Forbes•2 days ago
The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
- Motley Fool•4 days ago
Better Buy: AbbVie Inc. vs. Merck
The deck is stacked in favor of one of these big pharma stocks. But which one?
- Capital Cube•5 days ago
Merck & Co., Inc. – Value Analysis (NYSE:MRK) : October 13, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck & Co., Inc. a score of 47. Our analysis is based on comparing Merck & Co., Inc. with the following peers – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ... Read more (Read more...)
Markit•5 days agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $11.76 billion.
- InvestorPlace•5 days ago
Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
- Zacks•6 days ago
Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib
Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.
Capital Cube•6 days agoMerck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : October 12, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck & Co., Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
- The Wall Street Journal•7 days ago
[$$] Ebola Vaccines Show Promise in New Study
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...
- Reuters•7 days ago
Merck says will not seek approval of cholesterol treatment
Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings. In August, a large study on anacetrapib found that the treatment cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat tissue, leaving its commercial future uncertain. The treatment is part of a class known as CETP inhibitors designed to raise HDL, the so-called good cholesterol.
- Financial Times•8 days ago
[$$] Decoding cancer: hopes rise for a new age of precision medicine
Ever since scientists began decoding the human genome in 1990, doctors have predicted an age of "precision medicine" where patients are matched with drugs that target the specific genetic drivers ...
- TheStreet.com•8 days ago
KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers
Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.
- 24/7 Wall St.•8 days ago
KalVista Pharma Wins Big on Merck Collaboration
KalVista Pharmaceuticals saw its shares absolutely explode early on Tuesday after it was announced that the firm would be collaborating with Merck.
Markit•8 days agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $8.59 billion.
- Motley Fool•9 days ago
The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
New data on NewLink's lead drug puts some pep in this clinical-stage drug developers' step.
- Zacks•12 days ago
Here's What's Has Happened in the HCV Space Lately
A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.
- Reuters•13 days ago
Roche bladder cancer drug struggles as medics focus on survival
Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer. Many modern cancer drugs are approved on the basis of alternative clinical endpoints, such as tumour shrinkage or reduced risk of disease progression, but extending patients' lives remains the most important benchmark for oncologists. Latest data show Tecentriq's share of the bladder cancer market has slipped to 32 percent from around 45 percent before May's surprise clinical trial failure, according to an analysis on Thursday by Barclays analysts.
- Market Realist•13 days ago
Changes in Eli Lilly’s Valuation
On September 28, 2017, Eli Lilly was trading at a forward PE multiple of ~18.7x compared to the industry average of ~16.6x.
- The Wall Street Journal•14 days ago
[$$] LBO Profile: GHIF Uses PE Model to Tackle Global Health Challenges
Global Healthcare Investment Advisors LLC wants to generate more than just healthy financial returns with its deals. The New York-based firm, which does business as the Global Health Investment Fund, also ...
Capital Cube•14 days agoMerck & Co., Inc. : MRK-US: Dividend Analysis : September 15th, 2017 (record date) : By the numbers : October 4, 2017
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Merck & Co., Inc. with the following peers – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Roche Holding Ltd Genusssch., Novartis AG Sponsored ADR and Amgen Inc. ... Read more (Read more...)
